HUTCHMED Licenses KRAS-EGFR ATTC to GSK in Deal Worth Up to $1.3B
HCM sits 36% above its 52-week low of $9.77.
Summary
HUTCHMED granted GSK exclusive worldwide rights (ex-Greater China) to HMPL-A830, a first-in-class KRAS-EGFR ATTC, for a US$110 million upfront payment and up to US$1.185 billion in milestones, plus royalties.
Key Events · M&A and Partnerships · HCM
-
GSK Licensing Deal for HMPL-A830
Exclusive worldwide rights to develop and commercialize HMPL-A830, a first-in-class KRAS-EGFR ATTC, have been granted to GSK, excluding Mainland China, Hong Kong, Macau and Taiwan.
-
Upfront and Milestone Economics
The agreement includes a US$110 million upfront payment at closing, up to US$1.185 billion in development, regulatory and commercial milestones (total up to US$1.295 billion), and tiered royalties on net sales.
-
Platform Validation
HMPL-A830 is the first candidate from HUTCHMED's ATTC platform to be licensed to a global partner, following two candidates that have entered clinical development.
-
Development Timeline
HUTCHMED will run the global Phase I program, expected to start in H2 2026 (NCT07718581); GSK takes over subsequent development and commercialization outside Greater China.
Analysis · HCM · Life Sciences
A first-in-class KRAS-EGFR antibody-targeted therapy conjugate, HMPL-A830, has been out-licensed to GSK in a transaction valued at up to US$1.295 billion plus royalties. The US$110 million upfront payment is due at closing, subject to antitrust clearance. This marks the first time HUTCHMED has licensed a candidate from its ATTC platform to a global partner, validating the platform's commercial potential. The deal provides non-dilutive capital and shifts later-stage development costs to GSK outside Greater China, while HUTCHMED retains full rights in its home region. The agreement follows a string of positive clinical and regulatory milestones for HUTCHMED in 2026, reinforcing its position as a partner of choice in precision oncology.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 43.9% of the 578 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.54%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HCM was trading at $13.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $9.77 to $18.30. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.